Australian company Vaxxas, is developing the world-first vaccine patch.
The company is heading toward large-scale clinical trials of its needle-free vaccine delivery platform, which could be approved for commercial use within three to five years.
The patch used by Vaxxas has a surface of thousands of micro-projections – a quarter of a millimetre long and dry-coated in vaccine. The technology deposits vaccine when applied to the skin for several seconds. These deposit within the dense population of key immune cells in the skin, developing an efficient and effective immune response. | https://www.tri.edu.au/Vaxxas